Positive results from study of peginterferon lambda in the treatment of outpatients with mild to moderate Covid-19

In the ILIAD trial (n=60), those treated with a single dose of peginterferon lambda were 4.1-fold (95% CU 1.2-16.7; p=0.029) more likely to have viral clearance (VC) by day 7 than those who received placebo, with a median time to VC of 7 versus 10 days, respectively (p=0.038).

Source:

Biospace Inc.